Blood levels of the MUC5AC protein could help predict outcomes in people who have surgery for pancreatic ductal adenocarcinoma (PDA), the most common type of…
Pancreatic cancer
PANCREATIC CANCER
Drug combo may be effective as treatment for pancreatic cancer
A combination of drugs to block two proteins, called PRMT5 and Chk1, may be effective for the treatment of pancreatic cancer, according to new…
PANCREATIC CANCER
Immunotherapy implant promising for treating pancreatic cancers
A new approach in immunotherapy that can safely boost the body’s immune response has shown promise in hard-to-treat tumors like pancreatic cancers, a study…
PANCREATIC CANCER
Blocking FGFR2 may stop pancreatic cancer from developing
Blocking the activity of a protein called FGFR2 may prevent some pancreatic cancers from developing, a study in mice indicated. The study, “…
PANCREATIC CANCER
Cabometyx wins FDA approval for treating certain pancreatic cancers
The U.S. Food and Drug Administration (FDA) has granted its approval to the oral medication Cabometyx (cabozantinib) as a treatment for certain types of…
PANCREATIC CANCER
FDA grants orphan drug status to PEP-010 for pancreatic cancer
The U.S. Food and Drug Administration (FDA) has granted orphan drug status to Pep-Therapy‘s PEP-010, a potential first-in-class treatment for pancreatic cancer. The…
PANCREATIC CANCER
OSE2101 vaccine shows ‘promising benefit’ in pancreatic cancer trial
Treatment with the experimental cancer vaccine OSE2101, given in combination with standard chemotherapy, led to positive early results in a Phase 2 clinical trial…
PANCREATIC CANCER
SIL204 reduces tumors, slows spread in pancreatic cancer models
Administering Silexion Therapeutics‘ investigational therapy SIL204 under the skin effectively reduced the growth of primary tumors and their metastatic spread to various organs in…
PANCREATIC CANCER
Immunotherapy shows promise as treatment for pancreatic cancer
Treatment with CAN-2409, an immune-modulating anticancer therapy, showed promising trends toward improved survival in a Phase 2 clinical trial involving people with pancreatic cancer,…
PANCREATIC CANCER
Low muscle mass linked to worse outcomes with chemoradiotherapy
Low muscle mass in people with inoperable pancreatic cancer undergoing chemoradiotherapy, or CRT, was linked with more treatment-related toxicities and shorter overall survival in…
Recent Posts
- IMF launches Myeloma Action Month to raise global awareness this March
- Annamycin shows encouraging early results in Phase 2/3 AML clinical trial
- Clearnote’s blood test uses AI to spot pancreatic cancer in high-risk groups
- Being a caregiver requires constant, sometimes impossible, calculations
- Immuno-gene therapy for brain cancer tumors now on FDA fast track
